Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2012-04-05 Transaction in Own Shar…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Acquisition of own shares_FR (05-04).pdf
Transaction in Own Shares Classification · 99% confidence The document is titled "Acquisition d'actions propres dans le cadre de rémunérations variables à long terme du personnel" (Acquisition of own shares under long-term variable remuneration for personnel). It explicitly details the purchase of 1,000 UCB shares on the Brussels stock exchange on 30/03/2012, stating these shares were delivered to employees exercising stock options. This action directly relates to the company buying back or issuing its own shares, often as part of compensation or repurchase programs. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase/issuance. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K) as it focuses solely on a specific transaction, not comprehensive financial results. It is not a Director's Dealing (DIRS) as it concerns employee stock options/remuneration plans, not personal trades by directors/executives, although it is related to insider activity. Therefore, POS is the most accurate classification.
2012-04-05 French
Acquisition of own shares_NL (05-04).pdf
Transaction in Own Shares Classification · 99% confidence The document is titled 'Aankoop van eigen aandelen in het kader van langetermijnincentives toegekend aan het personeel' (Purchase of own shares in the context of long-term incentives granted to personnel). It explicitly states that UCB purchased 1,000 UCB shares on the Brussels stock exchange and delivered them to employees who exercised their stock options. This action—the company buying back its own shares for employee incentive plans—directly corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS.
2012-04-05 Dutch
UCB AND AMGEN INITIATE SCLEROSTIN ANTIBODY PHASE 3 PROGRAM IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS
Earnings Release Classification · 95% confidence The document text is a press release dated April 3, 2012, announcing that UCB's drug Neupro® has been approved by the U.S. Food and Drug Administration (FDA) for Parkinson's Disease and Restless Legs Syndrome. It details the drug's efficacy, safety profile, and provides background information on the diseases. This type of announcement, which communicates a significant regulatory event (FDA approval) and provides key clinical data summaries, is characteristic of an Earnings Release (ER) or a general press release related to company performance/developments. Since it is an initial announcement of a major event (FDA approval) and includes key highlights rather than being a comprehensive annual or quarterly report, the most fitting category is 'Earnings Release' (ER), as these releases often cover major corporate news alongside financial results, or sometimes stand alone for major non-financial news. Given the options, ER is the closest fit for a major, time-sensitive corporate announcement detailing a key product milestone, although 'Regulatory Filings' (RNS) could also be considered if it were purely a regulatory filing notification. However, the structure strongly suggests a formal press release intended for investors, aligning best with ER. Q2 2012
2012-04-04 English
UCB et Amgen lancent le programme de phase III sur l’anticorps de la sclérostine chez les patientes atteintes d’ostéoporose post-ménopausique
Earnings Release Classification · 95% confidence The document is a press release dated April 3, 2012, originating from UCB, announcing that the FDA has approved Neupro® (rotigotine) for Parkinson's disease and Restless Legs Syndrome (RLS). The text details the approval, clinical trial efficacy, safety information (including warnings about somnolence, hallucinations, impulse control disorders, and melanoma risk), and provides background on the diseases and the product. This format—a detailed announcement of a significant regulatory event (FDA approval) including clinical data summaries and safety warnings—is characteristic of an Earnings Release (ER) or a general press release related to product news. Since it focuses on the immediate announcement of a major regulatory milestone and provides key highlights rather than being a comprehensive annual filing (10-K) or a detailed quarterly report (IR), 'Earnings Release' (ER) is the most appropriate classification for a significant corporate/product news announcement, even if it's not strictly tied to a quarterly earnings cycle, as it serves the function of informing the market of material news. Given the context of financial reporting databases, major product approvals often fall under ER or RNS. As it contains substantial detail about the product and trials, it leans away from a simple RNS, making ER the best fit among the options for a major corporate announcement. Q2 2012
2012-04-04 French
UCB en Amgen starten fase-III-programma sclerostine-antilichamen bij patiënten met postmenopauzale osteoporose
Regulatory Filings Classification · 95% confidence The document is a press release dated April 2012, originating from Brussels/Atlanta, and explicitly labeled as "gereguleerde informatie" (regulated information). It announces the FDA approval of the drug Neupro® for Parkinson's disease and Restless Legs Syndrome, detailing clinical trial data, mechanism of action, and important safety information for both the US and EU markets. This type of announcement, which releases key, time-sensitive, non-financial operational/regulatory news to the public and markets, fits best under the category of a general regulatory announcement or press release. Since it is not a full Annual Report (10-K), a specific financial supplement (XLSX), a detailed management discussion (MDA), or a formal Earnings Release (ER) focusing only on financial figures, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such official, non-standardized announcements. It is not an RPA because it contains substantial content (clinical data, safety warnings, background info) rather than just announcing that a report is available.
2012-04-04 Dutch
Neupro® approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Earnings Release Classification · 95% confidence The document text is a press release dated April 3, 2012, announcing that UCB's drug Neupro® has been approved by the U.S. Food and Drug Administration (FDA) for Parkinson's Disease and Restless Legs Syndrome. It details the drug's efficacy, safety profile, and provides background information on the diseases. This type of announcement, which communicates a significant regulatory event (FDA approval) and provides key clinical data summaries, is characteristic of an Earnings Release (ER) or a general press release related to company performance/developments. Since it is an initial announcement of a major event (FDA approval) and includes key highlights rather than being a comprehensive annual or quarterly report, the most fitting category is 'Earnings Release' (ER), as these releases often cover major corporate news alongside financial results, or sometimes stand alone for major non-financial news. Given the options, ER is the closest fit for a major, time-sensitive corporate announcement detailing a key product milestone, although 'Regulatory Filings' (RNS) could also be considered if it were purely a regulatory filing notification. However, the structure strongly suggests a formal press release intended for investors, aligning best with ER. Q2 2012
2012-04-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.